Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
What happened
FDA reviewed records the company submitted after a July 7, 2025 request under section 704(a)(4) and reviewed its drug listing submissions; this was not an inspection. FDA found current good manufacturing practice (CGMP) deviations for active pharmaceutical ingredients (APIs), including missing process validation, incomplete batch records, unvalidated test methods, and no routine stability testing. FDA also found demecarium bromide and chlorambucil were not listed under the firm's own labeler code, and placed all drugs offered for import from the firm on Import Alert 66-40 on July 21, 2026.
What FDA found
FDA said the firm shipped APIs to U.S. pharmacies that make customized medicines under section 503A without adequate process validation, while telling FDA they were still in development.
FD&C Act section 501(a)(2)(B)Batch records lacked critical processing information and major equipment, and FDA said a requested batch record was not provided.
FD&C Act section 501(a)(2)(B)The firm did not validate or verify analytical test methods used for drugs sent to the U.S.
FD&C Act section 501(a)(2)(B)The firm did not run routine stability testing to support API expiry dates or storage conditions.
FD&C Act section 501(a)(2)(B)The firm did not list demecarium bromide and chlorambucil under its own labeler code even though it made and shipped them to the U.S.
FD&C Act section 510(j); 21 CFR 207.41
What FDA wants
FDA tells the firm to respond in writing within 15 business days to CDER, addressing the CGMP and drug listing deviations and providing the requested assessments, records, and corrective plans. The response must cite FEI 3012560989 and ATTN: Marva Taylor.
Who should pay attention
- 503A compounding pharmacies that received these APIs
- companies that buy or repackage APIs from this firm
- quality teams tracking supplier CGMP and drug listing
This is a summary. Read the original letter on fda.gov.